LawrenceS,KegelesMD

PubMed

• Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).
  William S Stone, Michael R Phillips, Lawrence H Yang, Lawrence S Kegeles, Jeffrey A Lieberman
  Schizophrenia Research. 2023-11-01
• 4 citations
  Detecting schizophrenia with 3D structural brain MRI using deep learning.
  Junhao Zhang, Vishwanatha M Rao, Ye Tian, Yanting Yang, Nicolas Acosta
  Scientific Reports. 2023-09-02
• 15 citations
  Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Tri...
  Pejman Sehatpour, Dan V Iosifescu, Heloise M De Baun, Constance Shope, Megan R Mayer
  Biological Psychiatry. 2023-07-15

Journal Articles

• A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom Mechanisms  
  Ragy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
• Neuromelanin-Sensitive MRI as a Noninvasive Proxy Measure of Dopamine Function in the Human Brain  
  Lawrence S Kegeles, Madeleine E Sharp, Jodi J Weinstein, Ragy R Girgis, Proceedings of the National Academy of Sciences
• Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention  
  Lieberman J, Girgis R, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall M, Corcoran C, Schobel S, Small S, Mol Psychiatry, 1/9/2018
• Multicenter validation study of biomarkers for glutamate-targeted drug development in psychotic disorders  
  JavittDC, Carter CS, KrystalJT, KantrowitzJT, GirgisRR, Kegeles LS, RaglandJD, MaddockR, TanaseC, CorlettPR, RothmanD, MasonG, PotterWZ, CarlsonM, WallMM, ChooT, Grinb..., JAMA Psychiatry, 1/1/2018
• Enhanced striatal dopamine release to expectation of alcohol: a potential risk factor for alcohol use disorder  
  Kegeles LS, Horga G, Ghazzaoui R, Rosengard R, Ojeil N, Xu X, Slifstein M, Petrakis I, O'MalleySS, Krystal JH, Abi-Dargham A, Biol Psychiatry Cogn Neurosci Neuroimaging, 1/1/2018
• PET imaging of dopamine-D2 receptor internalization in schizophrenia  
  Weinstein J, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A, Mol Psychiatry, 1/1/2017
• Deficits in striatal dopamine release in cannabis dependence  
  van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Ojeil N, Kegeles LS, Xu X, Vadhan NP, Volkow ND, Slifstein M, Abi-Dargham, A, Mol Psychiatry, 1/1/2017
• Pathway-Specific Dopamine Abnormalities in Schizophrenia  
  Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A, Biol Psychiatry, 1/1/2017
• Estimating the effect of endogenous dopamine on baseline [��C]-(+)-PHNO binding in the human brain  
  Caravaggio F, Kegeles LS, Wilson AA, Remington G, Borlido C, Mamo DC, Graff-Guerrero A, Synapse, 1/1/2016
• Brain GABA Detection in vivo with the J-editing 1H MRS Technique: A comprehensive methodological evaluation of sensitivity enhancement, macromolecule contamination and...  
  Shungu DC, Mao X, Gonzales R, Soones TN, Dyke JP, van der Veen JW, Kegeles LS, NMR Biomed, 1/1/2016
• A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder  
  Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ, Mol Psychiatry, 1/1/2016
• A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia  
  Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA, J Psychopharmacol, 1/1/2016
• Brain GABA Function and Psychosis (editorial)  
  Kegeles LS, Am J Psychiatry, 1/1/2016
• Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 Positron Emission Tomography Radiotracer [11C]ABP688 and Magnetic Resonan...  
  Martinez D, Slifstein M, Nabulsi N, Grassetti A, Urban NB, Perez A, Liu F, Lin SF, Ropchan J, Mao X, Kegeles LS, Shungu DC, Carson RE, Huang Y, Biol Psychiatry, 1/1/2014
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery  
  Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR, Mol Psychiatry, 1/1/2014
• Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings  
  Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR, Schizophr Res, 1/1/2014
• Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [��C]NNC112  
  Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ, Psychopharmacology (Berl), 1/1/2014
• Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [11C]DAS...  
  Urban NBL, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M, Neuropsychopharmacology, 1/1/2012
• Investigation of cortical glutamate-glutamine and y-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy  
  Simpson HB, Shungu DC, Bender J, Mao X, Xu X, Slifstein M, Kegeles LS, Neuropsychopharmacology, 1/1/2012
• Increased prefrontal cortical D1 receptors in drug na�ve patients with schizophrenia: a PET study with [11C]NNC 112  
  Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang D-R, Laruelle M, Slifstein M, J Psychopharmacol, 1/1/2012
• Elevated prefrontal cortex y-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy  
  Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC, Arch Gen Psychiatry, 1/1/2012
• Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET  
  Bullich S, Slifstein M, Passchier J, Murthy V, Kegeles LS, Kim JH, Xu X, Gunn RN, Herance R, Gispert JD, Gutierrez A, Farre M, Laruelle M, Catafau AM, Mol Imaging Biol, 1/1/2011
• Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride PET  
  Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A, Biol Psychiatry, 1/1/2010
• 99mTc Hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease  
  Devanand DP, Van Heertum RL, Kegeles LS, Liu X, Jin ZH, Pradhaban G, Rusinek H, Pratap M, Pelton GH, Prohovnik I, Stern Y, Mann JJ, Parsey R, Am J Geriatr Psychiatry, 1/1/2010
• Increased synaptic dopamine in associative regions of the striatum in schizophrenia  
  Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang D-R, Huang Y, Haber S, Laruelle M, Arch Gen Psychiatry, 1/1/2010
• Join now to see all

Books/Book Chapters

• Dopamine Handbook 
  Chapter: Dopamine dysfunction in schizophrenia. 
  Abi-Dargham A, Slifstein M, Kegeles L, Laruelle MEditors: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A.Oxford University Press, New York, NY2010
• Handbook of Medical Psychiatry 
  Chapter: Neuroimaging findings in schizophrenia: from mental to neuronal fragmentation. 
  Kegeles LS, Laruelle MEditors: Soares JC and Gershon S.Marcel Dekker, Inc., New York, NY2003
• Proceedings of the 9th International Catecholamine Symposium 
  Chapter: Dopaminergic hyperactivity in striatum in schizophrenia: a failure of cortical glutamatergic control? 
  Kegeles LS, Laruelle MKluwer Academic/Plenum Publishers, New York, NY2002
• Psychiatric Neuroimaging Research: Contemporary Strategies 
  Chapter: 'Functional' neuroreceptor imaging: the example of studies of synaptic dopamine activity with single photon emission computed tomography. 
  Lombardo I, Abi-Dargham A, Kegeles L, Laruelle MEditors: Dougherty DD, Rauch SL.American Psychiatric Publishing, Inc., Washington, DC2001
• Physiological Imaging of the Brain with PET 
  Chapter: Reproducibility of radioligand measurements of pharmacologically induced striatal dopamine release in humans. 
  Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Van Heertum RL, Mann JJ, Laruelle MEditors: Gjedde A, Hansen SB, Knudsen GM, Paulson OB.Academic Press, New York, NY2000
• Problems of Drug Dependence, NIDA Research Monograph, Proceedings of the 60th Annual Scientific Meeting 
  Chapter: Love at first sight: SPECT imaging of dopamine release following amphetamine challenge in healthy volunteers. 
  Laruelle M, Kegeles LS, Abi-Dargham ACollege on Problems of Drug Dependence, Inc.1998
• Schizophrenia: New Directions for Clinical Research and Treatment 
  Chapter: Brain Imaging in Schizophrenia. 
  Malaspina D, Kegeles LS, Van Heertum RLEditors: Kaufmann CA, Gorman JM.Mary Ann Liebert, Inc., Larchmont, NY1996
• Join now to see all

Abstracts/Posters

• The role of molecular imaging in guiding drug development.
  Abi-Dargham A, Kegeles LS, Slifstein M, Schizophrenia Bulletin; Symposium: The role of dopamine in shaping circuitry related to schizophrenia and addiction; 6th Biennial Schizophrenia International Research Society Conference, 1/1/2018
• Disturbances in neural oscillations, glutamate, and GABA: effects of ketamine and comparison to schizophrenia.
  Kegeles LS, Stolz E, Mao X, Ojeil N, Massuda R, Pedrini M, Bayatmokhtari M, Slifstein M, Abi-Dargham A, Milak M, Rodriguez C, Chen C-M, Shungu DC, Schizophrenia Bulletin; Symposium: Excitation-inhibition imbalances in schizophrenia: mechanisms and interventions; 6th Biennial Schizophrenia International Research Society Conference, 1/1/2018
• Schizophrenia and NMDA Receptor Deficiency: Rebalancing Excitation /
  Kegeles LS, Symposium: Excitation/Inhibition Balance Disturbances in Schizophrenia: From Circuits to Large-Scale Networks; 5th Schizophrenia International Research Society Conference, 1/1/2016
• Increased striatal dopamine release under expectation of alcohol as a risk biomarker for alcohol use disorders: a Positron Emission Tomography imaging study with [11C]...
  Kegeles LS, Horga G, Ghazzaoui R, Rosengard R, Xu X, Slifstein M, Petrakis I, O'Malley SS, Krystal JH, Abi-Dargham A, 55th American College of Neuropsychopharmacology Annual Meeting, 1/1/2016
• Inhibition Disturbances.
  Stolz E, Kegeles LS, Chrobak JJ, Chen C-MA, 44th Annual Meeting, The International Neuropsychological Society, Boston, MA, 1/1/2016
• GABA and glutamate dysfunction in schizophrenia: distinguishing medication effects from neurobiology.
  Kegeles LS, Mao X, Ojeil N, Bayatmokhtari M, Stanford AD, Girgis R, Gil R, Lisanby SH, Chen C-M, Slifstein M, Abi-Dargham A, Rodriguez C, Milak M, Shungu DC, Schizophrenia Bulletin, 1/1/2015
• Finding the sites of glutamate circuitry abnormality in schizophrenia with proton MRS.
  Kegeles LS, Mao X, Ojeil N, Massuda R, Pedrini M, Stanford AD, Girgis R, Gil R, Lisanby SH, Chen C-M, Slifstein M, Abi-Dargham A, Rodriguez C, Milak M, Shungu DC, Schizophrenia Bulletin, 1/1/2015
• Baseline [11C]raclopride binding potential is inversely related to D2/3 receptor stimulation by endogenous dopamine
  Kegeles LS, Martinez D, Slifstein M, Laruelle M, Abi-Dargham A, 53rd American College of Neuropsychopharmacology Annual Meeting, 1/1/2014
• J-editing/MEGA-PRESS time-course study of the neurochemical effects of ketamine administration in healthy humans.
  Kegeles LS, Mao X, Ojeil N, Massuda R, Pedrini M, Chen C-M, Slifstein M, Abi- Dargham A, Milak M, Rodriguez C, Shungu DC, Proc Intl Soc Mag Reson Med, 1/1/2013
• Time course of ketamine effects on brain glutamate and GABA levels measured with 1H MRS.
  Kegeles LS, Mao X, Ojeil N, Massuda R, Pedrini M, Chen C-M, Slifstein M, Abi-Dargham A, Milak M, Rodriguez C, Shungu DC, Schizophrenia Bulletin, 1/1/2013
• Neurochemical effects of ketamine administration in healthy humans: an MRS time-course study
  Kegeles LS, Mao X, Ojeil N, Massuda R, Pedrini M, Chen C-M, Slifstein M, Abi-Dargham A, Milak M, Rodriguez C, Shungu DC, 51st Annual American College of Neuropsychopharmacology Meeting, 1/1/2012
• The 5-HT2A receptor and serotonin transporter in ecstasy users: a PET Study with [11C]MDL 100907 and [11C]DASB
  Girgis RR, Urban NB, Talbot P, Kegeles LS, Thompson JL, Xu X, Frankle WG, Slifstein M, Abi-Dargham A, Laruelle M, 50th Annual American College of Neuropsychopharmacology Meeting, 1/1/2011
• GABA and glutamate-glutamine in schizophrenia measured with proton Magnetic Resonance Spectroscopy
  Kegeles LS, 50th Annual American College of Neuropsychopharmacology Meeting, 1/1/2011
• 1H MRS provides evidence of altered frontal cortex GABA and glutamate-glutamine in schizophrenia in vivo.
  Kegeles LS, Mao X, Stanford A, Ojeil N, Alvarez B, Girgis RR, Gil R, Abi-Dargham A, Lisanby SH, Shungu DC, Proc Intl Soc Mag Reson Med, 1/1/2011
• Frontal cortex GABA, oscillations, and working memory in schizophrenia.
  Kegeles LS, Chen C-M, Mao X, Stanford A, Shungu DC, Lisanby SH, Schizophrenia Bulletin, 1/1/2011
• Combined PET and MRS study of neurochemistry of obsessive-compulsive disorder.
  Kegeles LS, Simpson HB, Xu X, Mao X, Staub R, Bender J, Slifstein M, Shungu DC, Abi-Dargham A, J Nucl Med, 1/1/2010
• Neurochemistry of obsessive-compulsive disorder: a combined PET and MRS study.
  Kegeles LS, Simpson HB, Xu X, Mao X, Staub R, Bender J, Medina O, Slifstein M, Shungu DC, Abi-Dargham A, NeuroImage, 1/1/2010
• GABA, neuronal synchrony, and working memory performance in schizophrenia.
  Kegeles LS, Chen C-M, Mao X, Stanford A, Shungu D, Lisanby SH, Neuropsychopharmacology, 1/1/2010
• Combining PET and MRS to study the neurochemistry of obsessive-compulsive disorder.
  Simpson HB, Kegeles LS, Xu X, Mao X, Bender J, Maher M, Staub R, Medina O, Slifstein M, Shungu D, Abi-Dargham A, Neuropsychopharmacology, 1/1/2010
• MRS measurement of GABA and glutamate-glutamine in frontal cortex in obsessive-compulsive disorder.
  Kegeles LS, Simpson HB, Mao X, Staub R, Shungu DC, Proc Intl Soc Mag Reson Med, 1/1/2010
• Frontal cortex GABA and glutamate-glutamine levels in schizophrenia: a magnetic resonance spectroscopy study
  Kegeles LS, Mao X, Stanford A, Ojeil N, Alvarez B, Castillo F, Gil R, Abi-Dargham A, Lisanby S, Shungu DC, 48th Annual American College of Neuropsychopharmacology Meeting, 1/1/2009
• Frontal cortex GABA and glutamate-glutamine levels in schizophrenia measured with magnetic resonance spectroscopy.
  Kegeles LS, Mao X, Stanford A, Sakr E, Alvarez B, Gil R, Abi-Dargham A, Lisanby SH, Shungu DC, Biol Psychiatry, 1/1/2009
• D2/D3 receptor binding in striatal and extrastriatal regions in schizophrenia studied with PET and [18F]fallypride.
  Kegeles LS, Slifstein M, Xu X, Hackett E, Gil R, Alvarez B, Meyers E, Urban N, Laruelle M, Abi-Dargham A, Schizophrenia Bulletin, 1/1/2009
• D2/D3 receptor binding in striatal and extrastriatal regions in schizophrenia: a PET study with [18F]fallypride
  Kegeles LS, Slifstein M, Xu X, Hackett E, Gil R, Alvarez B, Meyers E, Urban N, Laruelle M, Abi-Dargham A, 47th Annual American College of Neuropsychopharmacology Meeting, 1/1/2008
• [18F]Fallypride PET assessment of D2/D3 receptor binding in schizophrenia.
  Kegeles LS, Slifstein M, Xu X, Hackett E, Castrillon J, Bae S-A, Urban N, Laruelle M, Abi-Dargham A, J Nucl Med, 1/1/2008
• Join now to see all

Lectures

• Excitation/Inhibition Imbalances in Schizophrenia 
  New York Medical College, Valhalla, NY - 1/1/2017
• Neuroreceptor Imaging of Neurotransmitter Abnormalities 
  Chicago, IL - 1/1/2015
• Positron Emission Tomography Studies in Early Stages of Schizophrenia 
  Cancun, Mexico - 1/1/2015
• GABA and Glutamate as potential therapeutic targets in schizophrenia. 
  1/1/2014
• NMDA Receptor Hypofunction in Schizophrenia: PET and MRS Studies 
  Mexico City, Mexico - 1/1/2014
• MR Spectroscopy and NMDA Receptor Hypofunction in Schizophrenia 
  University of New Mexico, Albuquerque, NM - 1/1/2013
• Taking Stock of Glutamate in Schizophrenia 
  1/1/2013
• Gamma-Aminobutyric Acid Alterations Across Psychiatric Disorders 
  Phoenix, AZ - 1/1/2012
• PET Neuroreceptor Approaches to Biomarkers of Neurotransmitter Abnormalities 
  Montabaur, Germany - 1/1/2011
• Imaging Neurotransmitters in Schizophrenia 
  Elmhurst Hospital, New York, NY - 1/1/2010
• Test-retest reliability of dorsolateral prefrontal cortical GABA and glutamate/glutamine measurement with the J-edited spin echo difference technique at 3T. 
  1/1/2005
• Relationship of paternal age to neuronal functional integrity in the prefrontal cortex in schizophrenia determined by 1H MRS. 
  1/1/2005
• Applications of MR Spectroscopy to Neuroscience 
  Columbia University - 1/1/2003
• Prefrontal D1 Receptors and Working Memory in Schizophrenia 
  St. Vincent�s Hospital, New York, NY - 1/1/2001
• MRI/MRS Study of Glutamate in Schizophrenia 
  New York, NY - 1/1/1996
• On slow-motion expansions in general relativity. 
  1/1/1979
• Join now to see all